3.8 Article

Variances in BCG protection against COVID-19 mortality: A global assessment

Publisher

ELSEVIER
DOI: 10.1016/j.jctube.2021.100249

Keywords

Coronavirus; BCG vaccine; Policy; Innate immunity; Heterologous immunity

Ask authors/readers for more resources

The BCG vaccine is known for providing protection against tuberculosis and potential benefits in preventing bladder cancer and respiratory infections. During the COVID-19 pandemic, the BCG vaccine has garnered attention for its potential role in conferring protective immunity. Research has revealed the potential immunological mechanisms of BCG vaccines against COVID-19.
The BCG vaccine is known to impart nonspecific immunological benefits alongside conferring protection to tuberculosis in endemic regions. It is also known to protect against bladder cancer and other respiratory tract infections. During the coronavirus disease 2019 (COVID-19) pandemic, the BCG vaccine has gained attention due to its role in conferring protective immunity. We demonstrate the potential immunological protective mechanisms that play a role against COVID-19. We conduct a global assessment of the countries that have the highest and lowest mortality rates determined by an a priori methodology. Lastly, we discuss the potential limitations of incorporating BCG vaccines as potential strategies against COVID-19 and provide recommendations regarding their use in ongoing and future epidemics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available